Back to news

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Globe Newswire•16/11/2026•07:05 ET
0

Key Highlights

  • ➤FDA accepted OLC NDA resubmission; PDUFA target action date set for March 25, 2027
  • ➤Cash, equivalents, and marketable securities totaled approximately $59 million at September 30, 2026
  • ➤Q3 net loss widened to $7.0 million, or $0.25 per share
  • ➤Q3 G&A expense rose to $6.6 million, including $1.4 million for commercial launch preparation
  • ➤CMS added $12.85 per dialysis treatment to the 2027 base rate for phosphate binders

Expert Statements

Shalabh Gupta, Chief Executive Officer of Unicycive Therapeutics

“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients”

Shalabh Gupta, Chief Executive Officer of Unicycive Therapeutics

“With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”

* New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (PDUFA) date of March 25, 2027

* As of September 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $59 million, with expected runway beyond 2027, including the cost of potential OLC launch MOUNTAIN VIEW, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in